A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Gabapentin (GABARONE)

Gabapentin Capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, ....

First FDA approval1993-12-30
Generic availableYes · 28 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$879.9M in CY2024 Part D spend55.4M claims · 14.5M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.021/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.021
Across all dosage forms in distribution.
Highest NADAC
$0.021
Range is tight.
Plans with PA
136 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Gabapentin used for?

Gabapentin Capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, ....

Is there a generic for Gabapentin?

Yes. 102 ANDAs filed at FDA, 28 generic manufacturers currently shipping.

How much does my plan pay for Gabapentin?

Across 329 Part D plans, Gabapentin averages $0.021/unit (NADAC). Lowest available: $0.021/unit. Highest in distribution: $0.021/unit.

Is Gabapentin on the FDA shortage list?

No. Gabapentin is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Anticonvulsant / Neuropathic Pain Agent1 alternative in D1
01
Pregabalin
Brand: Lyrica
$0.046Lowest NADAC
28Generic mfrs
$382.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.